Takeda Revenue and Competitors

Chicago, IL USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Takeda's estimated annual revenue is currently $200.6M per year.(i)
  • Takeda's estimated revenue per employee is $195,324
  • Takeda's current valuation is $45.9B. (January 2022)

Employee Data

  • Takeda has 1027 Employees.(i)
  • Takeda grew their employee count by 5% last year.

Takeda's People

NameTitleEmail/Phone
1
Head Epidemiology, Takeda Vaccines Business Unit .Reveal Email/Phone
2
Head Insights and Analytics, Takeda R&D Data Sciences InstituteReveal Email/Phone
3
VP, Head Rare Diseases, Europe & CanadaReveal Email/Phone
4
VP National Sales and Accounts, GIReveal Email/Phone
5
Head Business ExcellenceReveal Email/Phone
6
SVP, U.S. Rare Disease Business Unit LeadReveal Email/Phone
7
Head Industrial AutomationReveal Email/Phone
8
Director - Chief Financial OfficerReveal Email/Phone
9
Director, State Government AffairsReveal Email/Phone
10
Associate Director, Strategic Insights Partner, GI Global CommercialReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13.1M6530%N/AN/A
#2
$75.6M3767%N/AN/A
#3
$23.9M11913%$35MN/A
#4
$12.7M63-3%N/AN/A
#5
$5.4M27-25%N/AN/A
#6
$6M30-35%N/AN/A
#7
$6.6M33-8%N/AN/A
#8
$13.5M67-3%N/AN/A
#9
$186.3M92719%N/AN/A
#10
$4.4M22-4%N/AN/A
Add Company

What Is Takeda?

In1781,Chobei Takeda I begins selling traditional Japanese and Chinese herbal medicines in Doshomachi , the medicine district of Osaka, Japan. Takeda’s founder gains a reputation for business integrity and quality products and services. These characteristics and values continue through the years and become embeded into our uncompromising corporate philosophy, which still guide us today.

keywords:N/A

N/A

Total Funding

1027

Number of Employees

$200.6M

Revenue (est)

5%

Employee Growth %

$45.9B

Valuation

N/A

Accelerator

Takeda News

2022-04-20 - Moving on from Usama Malik's insider trading imbroglio, Fore ...

... ? The ouster of former Immunomedics exec Usama Malik created a CEO opening at Fore Biotherapeutics, which is taking aim at BRAF...

2022-04-20 - Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay

These data announcements follow completion of patient enrollment in Takeda's AURORA (TAK-620-302) study, focusing on LIVTENCITY for first-line...

2022-04-20 - Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay

These data announcements follow completion of patient enrollment in Takeda's AURORA (TAK-620-302) study, focusing on LIVTENCITY for first-line...

2022-04-20 - Moving on from Usama Malik's insider trading imbroglio, Fore ...

... ? The ouster of former Immunomedics exec Usama Malik created a CEO opening at Fore Biotherapeutics, which is taking aim at BRAF...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$384.5M11498%N/A
#2
$201.6M12002%N/A
#3
$312.5M1240N/AN/A
#4
$268.9M13388%N/A
#5
$300M15636%N/A